Significance Statement {#s5}
======================

The polyamines are a group of molecules that play an essential role in various physiological functions of the mammalian CNS. Previous literature has indicated alterations in the expression of polyamine-related genes in the brains of individuals who died by suicide, including downregulation of spermidine/spermine N1-acetyltransferase (SAT1), a key enzyme involved in polyamine catabolism. In a previous report of ours, we showed evidence of elevated levels of the polyamines putrescine and spermidine in the cortex of depressed suicides compared with controls. Agmatine, another member of the polyaminergic system, has been extensively implicated as an antidepressant in preclinical models of depressive-like behavior. However, agmatine concentrations have not been explored in postmortem human brain of individuals who died by suicide. Here we describe such an investigation and reveal that agmatine levels are reduced in the cortex of suicides. The novel findings of this study further implicate a role of the polyaminergic system in the neurobiology of depression and suicide.

Introduction {#s6}
============

The polyamines are a group of ubiquitous low-molecular--weight aliphatic molecules that include agmatine, ((4-aminobutyl) guanidine), putrescine (1,4-diaminobutane), spermidine (N-\[3-aminopropyl\]-1,4-diaminobutane), and spermine (N,N-bis\[3-aminopropyl\]-1,4-diaminobutane). In mammals, polyamines play essential roles in various physiological functions, including cell proliferation, signaling and apoptosis, immunity, neurotransmission, adult brain neurogenesis, and stress regulation at both the cellular and behavioral levels ([@CIT0034]). The majority of brain polyamines are stored in astrocytes and synaptic vesicles, allowing for their place in glial and neuronal communication. For instance, in the brain polyamines are synthesized in neurons, stored in synaptosomes, and released to modulate neurotransmission through ionotropic glutamate receptors such as *N*-methyl---aspartate (NMDA) receptors and alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors (as reviewed in [@CIT0034]).

Alterations in the expression of the polyamines and their metabolic enzymes have been found in many psychiatric illnesses, including schizophrenia ([@CIT0023]), mood disorders ([@CIT0022]), stress and anxiety ([@CIT0017]), addiction ([@CIT0001]), and suicidal behavior ([@CIT0035], [@CIT0036]; [@CIT0038]).

Gene expression studies using postmortem human brain samples have consistently revealed dysregulation of the polyamine system in major depressive disorder (MDD) and suicide. The first study showed a significant decrease in gene and protein expression of spermidine/spermine N1-acetyltransferase (SAT1), a key enzyme responsible for polyamine catabolism, in Brodmann areas 4, 8/9, and 11 in both nondepressed suicides and MDD suicides compared with controls ([@CIT0035]). This finding was subsequently confirmed by independent studies and different groups across various brain regions and sample populations ([@CIT0036]; [@CIT0018], [@CIT0019]; [@CIT0010]; [@CIT0032]).

As such, there has been considerable interest in the polyaminergic system as a promising candidate for the treatment of CNS diseases, particularly depression. In fact, preclinical data indicate that agmatine specifically may act as an endogenous antidepressant compound. [@CIT0041] were first to describe antidepressant-like effects of agmatine on mouse immobility during the forced swimming test and tail suspension test. Using the same behavioral measures of depressive-like behavior, [@CIT0020] revealed an antidepressant-like effect produced by agmatine in both mice and rats. A significant number of follow-up studies have investigated the potential mechanisms through which agmatine exerts its antidepressant-like effects. One such mechanism includes blockade of NMDA receptors and inhibition of NOS ([@CIT0041]), which may thus result in protection against NMDA-induced cytotoxicity ([@CIT0020]). More recent evidence has also suggested that agmatine has fast-acting antidepressant properties comparable with those of the NMDA antagonist ketamine ([@CIT0027]; [@CIT0029]). Antidepressant-like effects of agmatine have also been shown to be mediated through an interaction with 5-HT(1A/1B) and 5-HT(2) receptors ([@CIT0042]; [@CIT0016]), μ- and δ-opioid receptors ([@CIT0043]), alpha2 receptors ([@CIT0016]), activation of monoaminergic systems ([@CIT0028]), its effects on neurogenesis ([@CIT0021]), and activation of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid and TrkB receptors ([@CIT0030]). Most recently, agmatine was shown to attenuate chronic unpredictable mild stress-induced anxiety- and depressive-like behavior by inhibiting serum CORT and raising BDNF levels ([@CIT0012]). In extension to these findings, a clinical study by [@CIT0037], albeit a small sample size, showed an antidepressant effect of exogenous agmatine on depressed subjects. Participants in the study achieved total illness remission without physical or behavioral side effects.

To our knowledge, agmatine concentrations have yet to be explored in postmortem human brain of suicides. The aim of the present study was to employ our previously published negative ion chemical ionization (NCI)-GC-MS method ([@CIT0006]) for quantitation of agmatine in postmortem human brain to investigate cortical brain concentrations of agmatine in suicides who met criteria for a diagnosis of MDD, suicides who did not, and controls.

Methods {#s7}
=======

Subjects and Diagnostic Procedures {#s8}
----------------------------------

Our sample consisted of 120 brain tissue samples from 40 male subjects of French-Canadian origin, including 13 control subjects (C), 14 subjects who died by suicide and met criteria for MDD (DS), and 13 subjects who died by suicide but did not meet criteria for MDD (NDS). We chose an only-male sample to avoid sex-related heterogeneity because sex-specific differences in levels of polyamines and their metabolic enzymes, as well as responses to polyamine exposure, have been reported ([@CIT0009]; [@CIT0013]; [@CIT0003]; [@CIT0002]). All subjects collected by the brain bank died suddenly without a prolonged agonal period. Controls died either in accidents or by natural death; cases and controls were matched for age, pH, and postmortem interval (PMI). Psychiatric diagnoses were obtained using the psychological autopsy method with the Structured Clinical Interview for DSM-IV Axis I, as described elsewhere ([@CIT0008]). Written informed consent was obtained for all subjects from next of kin. This study was approved by our local institutional review board. Postmortem brain tissues were obtained from the Douglas--Bell Canada Brain Bank (<http://www.douglas.qc.ca/page/brain-bank>) in which they were processed and dissected at 4°C and snap-frozen in liquid nitrogen before storage at −80°C following standard procedures ([@CIT0005]). Brain tissue dissection was performed following standard procedures and anatomical landmarks ([@CIT0031]; [@CIT0025]). Specifically, we focused on Brodmann areas 4 (motor cortex), 11(orbital cortex), and 44 (prefrontal cortex); the former 2 were brain regions used in our original report indicating SAT1 differential expression in suicide ([@CIT0035]) and another report showing elevated levels of putrescine and spermidine in suicide ([@CIT0007]). Brodmann area 44 was previously used to provide evidence that various epigenetic mechanisms contribute to the differential expression of polyaminergic genes in suicide ([@CIT0010]; [@CIT0011]; [@CIT0014]; [@CIT0024]).

NCI-GC-MS Method for Analysis Agmatine {#s9}
--------------------------------------

For effective extraction and quantitation of agmatine from a small quantity of postmortem human brain tissue, we used an NCI-GC-MS method previously developed in our laboratory ([@CIT0006]). Briefly, this method includes a negative chemical ionization GC-MS with a selected ion monitoring (SIM) technique. This allowed us to accurately measure agmatine to the level of 0.1 ng/mg of wet brain tissue level. ^15^N~4~-agmatine was used as the internal standard for endogenous agmatine, and an authentic agmatine compound was used as a standard for calibration. A selected ion chromatogram for agmatine, extracted from the cerebral cortex of a control brain and one from a suicide brain with spiked internal standard ^15^N~4~-agmatine is given in [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}.

GC-MS Conditions {#s10}
----------------

NCI was used in full scan, and SIM mode was carried out for all measurements with an Agilent HP6890/MSD5973N Chemstation system (Agilent Technologies. Inc. Santa Clara, CA). The methane gas (99.99%) was set at 2.0 mL/min and helium flow at 1.0 mL/min. The tuning compound used for NCI was perfluoro-5,8-dimethyl-3,6,9-trioxidodecane. An HP-5MS capillary column was used for the analysis. The following GC program was employed: 110 to 210°C at 30°C/min, hold at 210°C for 2 minutes, then increase to 320°C at 20°C/min and held for 4 minutes to bake out. MS conditions were: source 120°C, quadrupole 110°C, interface 260°C, injector 270°C. Full scan started at 5.45 minutes and ended at 15 minutes. The SIM ions monitored were m/z 496 (M-) and 476 (M-HF) for the ^15^N4-agmatine HFAA derivative and 492 (M-), and 472 (M-HF) for the ^14^N4-agmatine-HFAA derivative.

Data Analysis {#s11}
-------------

GC-MS data analysis was carried out with Chemstation software (Agilent Technologies). Statistical analyses were performed using SPSS 22.0. Pearson correlations were used to assess relationships between sample characteristics such as age, pH, and PMI with agmatine concentrations. To determine if there was an effect of alcohol dependence, age, pH, or PMI on agmatine concentrations, we conducted a 2-way ANCOVA with group and alcohol dependence as fixed factors and age, pH, and PMI as covariates. All nonsignificant variables were then removed and the most parsimonious model was employed. Each brain area was analyzed separately, and the normality assumption for the residuals of each model was tested via the Shapiro Wilks test. Bonferroni posthoc comparisons were used to analyze agmatine differences between clinical groups (C, DS, and NDS).

Results {#s12}
=======

Clinical and Demographic Features {#s13}
---------------------------------

[Supplementary Table 1](#sup1){ref-type="supplementary-material"} lists the demographic and clinical characteristics of the subjects included in this study according to groups. DS and NDS cases, as well as controls, had similar demographic characteristics, with no significant differences in age (F(2,37)=1.122, *P*=.336), PMI (F(2,37)=1.560, *P*=.224), or pH (F(2,37)=0.276, *P*=.761).

Analysis of Agmatine Levels {#s14}
---------------------------

Representative mass spectra are shown in [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}. Levels of agmatine were within the expected nanogram range. Agmatine concentrations did not significantly correlate with age, pH, or PMI in any brain region (see [Supplementary Table 2](#sup1){ref-type="supplementary-material"}).

A 2-way ANCOVA revealed a significant main effect of group (BA 4: F(2,31)=25.798, *P*=2.53×10^−7^; BA 11: F(2,31)=20.756, *P*=2.0×10^−6^; BA 44: F(1,31)=18.881, *P*=4.0×10^−6^) but no effect of alcohol dependence on agmatine concentrations. The interaction between group and alcohol dependence was not significant, nor were there significant effects of age, pH, or PMI in any region (see [Supplementary Table 3](#sup1){ref-type="supplementary-material"}). The residuals of each model were normally distributed.

A 1-way ANOVA, including only group as a fixed factor, revealed a significant effect of group on agmatine levels in BA 4 (F(2,37)=32.529, *P*=7.04×10^−9^), BA 11 (F(2,37)=24.416, *P*=1.73×10^−7^), and BA 44 (F(2,37)=24.022, *P*=2.06×10^−7^). The residuals of each model were normally distributed. For all 3 brain regions, Bonferroni adjusted posthoc comparisons revealed a significant difference between DS and controls (*P*\<.001) and between NDS and controls (*P*\<.001). Comparisons between DS and NDS were not significant for BA 4 (*P*=.137), BA 11 (*P*=.220), and BA 44 (*P*=.179) ([Figure 1](#F1){ref-type="fig"}).

![Agmatine concentrations in postmortem brain tissues by brain area and group. Concentrations (ng/mg)±SEM were obtained from controls (n=13), subjects who died by suicide and met criteria for MDD (n=14), and subjects who died by suicide but did not meet criteria for MDD (n=13) for Brodmann areas 4, 11, and 44. \*\**P*\<.001.](pyy05801){#F1}

There was no overall effect of brain area on agmatine concentrations (F(2,117)=1.982, *P*=.142) ([Figure 2](#F2){ref-type="fig"}).

![Overall agmatine concentrations in postmortem brain tissue by brain area. Concentrations (ng/mg)±SEM were determined by combing all groups and comparing across Brodmann areas 4 (n=40), 11 (n=40), and 44 (n=40).](pyy05802){#F2}

Discussion {#s15}
==========

Using an NCI-GC-MS method specifically designed for measuring agmatine concentrations in postmortem brain tissues, we were able to successfully determine agmatine levels in tissue samples from 3 brain regions obtained from 40 male subjects. We found significant decreases in agmatine concentrations across all 3 Brodmann areas (B4, 11, 44), for both suicide groups, irrespective of MDD diagnosis, compared with controls. We did not find a significant difference in overall agmatine concentrations across brain areas.

Our present findings are in agreement with a previous study of ours using an overlapping sample and 2 of the same brain areas, which found elevated putrescine and spermidine levels in cortical tissue samples of suicides ([@CIT0007]).

Agmatine is inactivated through hydrolyzation, by agmatinase, to produce putrescine. Thus, elevated levels of putrescine may be due in part to over active biosynthesis from its agmatine precursor. One explanation for this finding is that agmatinase may be overexpressed and/or displays higher enzymatic activity in the brains of suicides. Agmatine would therefore be more efficiently converted to putrescine, thereby reducing its levels. This hypothesis is supported by immunohistochemical evidence of increased agmatinase expression in hippocampal interneurons of individuals with affective disorder, most of whom died by suicide ([@CIT0004]). Agmatine has been shown to suppress ornithine decarboxylase (ODC) activity in numerous cell lines ([@CIT0040]). Another interpretation is that less agmatine would result in less ODC suppression and therefore increased putrescine biosynthesis through its conventional pathway. Interestingly, we have previously shown increased expression of 2 antizymes, OAZ1 and OAZ2, which directly inhibit ODC activity and protein levels ([@CIT0010]). Translation of each antizyme is controlled by a unique frameshift that is induced by elevated polyamine levels ([@CIT0026]). Taking into account the presence of increased polyamine levels ([@CIT0007], in conjunction with elevated antizyme mRNA levels, it seems likely that protein levels of antizyme are also increased as a potential regulatory response targeted at decreasing ODC activity in these brain regions. However, lower agmatine may impinge upon this natural negative feedback mechanism responsible for regulating ODC activity and downstream polyamine levels.

Taken together, our previous report of elevated putrescine and spermidine levels in the brain of suicides may be due in part to overactive biosynthesis of the former 2 polyamines and depletion of agmatine. Reduced SAT1 gene and protein expression may thus be a consequence of a compensatory mechanism intended to counter the overactive biosynthesis of putrescine and indicative of an improper polyamine stress response. Although we did not find a difference between MDD suicides and non-MDD suicides, it is reasonable to speculate that agmatine changes may associate with depressed mood. Whether meeting criteria for MDD or not, individuals who die by suicide do so while depressed and hopeless.

In contrast to our findings in postmortem tissue, increased plasma concentrations of agmatine have been reported in depressed subjects compared with controls ([@CIT0015]). While agmatine is able to cross the blood brain barrier ([@CIT0033]), the relationship between its concentrations in plasma vs brain is not yet clear in depression and/or suicide. Given that our reported findings in postmortem tissue are in the opposite direction as the aforementioned study, central concentrations may be inversely related to those in the periphery. Interestingly, increased plasma agmatine concentrations have also been reported in both plasma and postmortem brain samples from schizophrenic individuals ([@CIT0039]; [@CIT0023]). Therefore, a crucial avenue to explore would be to examine agmatine concentrations in both postmortem brain and plasma samples from individuals who died by suicide. Furthermore, understanding how agmatine concentrations vary in other Brodmann areas, which may not be related to mood, would help clarify whether dysregulation is region specific. This is, in fact, likely to be the case, as evidence for region-specific gene expression differences in suicide has been reported ([@CIT0010]). A final and equally important question to explore would be to tease apart the effects of depression vs suicide by investigating postmortem concentrations of agmatine in cortical samples of individuals who were depressed but did not die by suicide. Nevertheless, our previous findings of elevated putrescine and spermidine levels coupled with our current findings of reduced agmatine levels in the brains of individuals who died by suicide further implicate a role of the polyamine stress response in the neurobiology of depression and suicide.

Supplementary Materials {#s16}
=======================

Supplementary data are available at *International Journal of Neuropsychopharmacology (IJNPPY)* online.

###### 

Click here for additional data file.

Funding {#s17}
=======

G.T. holds a Canada Research Chair (Tier 1) and a NARSAD Distinguished Investigator Award. He is supported by grants from the Canadian Institute of Health Research (CIHR) (FDN148374 and EGM141899), by the FRQS through the Quebec Network on Suicide, Mood Disorders and Related Disorders, and through an investigator-initiated research grant from Pfizer. D.A. is a Vanier Scholar funded by the CIHR.

We thank the Douglas Bell Canada Brain Bank for providing the human postmortem brain tissue for this study.

Statement of Interest {#s18}
=====================

None

[^1]: G.G.C. and D.A. contributed equally to this work.
